Alamar Biosciences ALMR 深 沪
已收盘 08-14 16:00:00 美东时间
33.16
+0.240
+0.73%
华盛通- 最 高33.81
- 今 开33.81
- 成交量 16.11万股
- 最 低 32.61
- 昨 收 32.92
- 总市值 22.98亿
- 52周最高 38.54
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 18.845
- 委 比 -20.00%
- 总股本 6931.12万
- 历史最高 38.54
- 量 比 0.28
- 振 幅 3.65%
- 历史最低 18.845
- 每 手 1
- 风险率 3.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 3 Health Care Stocks That May Implode In August
As of Aug. 12, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices ...
08-12 20:58
美股牛股 | 绩优股普升！量子计算股昆腾飙升64%，NIQ劲升42%
绩优股普升！量子计算公司昆腾飙升64%，近三年来首度非GAAP单季盈利；NIQ劲升42%，Q2 EPS扭亏大幅增长；Fermi升逾21%，签署大规模AI数据中心长期租约>>
08-12 15:54
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
JP Morgan Maintains Overweight on Alamar Biosciences, Raises Price Target to $35
JP Morgan analyst Casey Woodring maintains Alamar Biosciences (NASDAQ:ALMR) with a Overweight and raises the price target from $32 to $35.
08-11 22:09
Quantum, Kopin, Alamar Biosciences And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Tuesday. Shares of Quantum Corp (NASDAQ:QMCO) rose sharply during Tuesday’s session after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Quantu...
08-11 22:08
Alamar Biosciences Sees FY2026 Sales $116.000M-$120.000M vs $113.259M Est
Alamar Biosciences (NASDAQ:ALMR) sees FY2026 sales of $116.000 million-$120.000 million vs $113.259 million analyst estimate.
08-11 04:42
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
Alamar Biosciences expands its partnership with Alzheimer's Disease Data Initiative and Gates Ventures, adding 86,000 plasma samples using NULISAseq™ Neuro 220 to study neurodegenerative disease heterogeneity. The combined dataset, expected to include over 140,000 samples by 2027, aims to provide deeper insights into disease subtypes and trajectories through multiplex protein profiling.
08-10 20:03
前再鼎医药总裁创办的Attovia上市：市值9.4亿美元 路演PPT曝光
雷递网 雷建平 8月6日 Attovia Therapeutics发行价为17美元，发行1700万股，募资总额为2.89亿美元。若承销商全额行使以同等价格额外认...
08-06 17:33
美股异动 | 生物科技公司Attovia Therapeutics(ATTO.US)登陆纳斯达克 上市首日收涨28.82%
周三，生物科技公司Attovia Therapeutics(ATTO.US)正式登陆纳斯达克，上市首日收涨28.82%，报21.9美元。IPO价格为17美元。...
08-06 06:18
生物科技IPO热潮延续！高盛系免疫疗法新锐Attovia(ATTO.US)IPO募资2.89亿美元，今晚登陆纳斯达克
专注于免疫系统疾病领域、致力于满足巨大未满足临床需求的早期生物制药公司Attovia Therapeutics Inc.(ATTO.US)，近日在美国首次公开募...
08-05 11:57
